REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
The SNX8 protein, even though is very similar to the other sorting nexins, presents a domain structure which resembles the most to SNX1's and SNX9's; for this reason, although its terciary structure remains unknown, it theoretically resembles that of SNX9 shown in the model above. Overall, the SNX8 protein is integrated by one unique peptide chain that has 465 amino acids with a molecular mass of 52.569 Da.
The most widespread use of 241AmBe neutron sources is a neutron probe – a device used to measure the quantity of water present in soil, as well as moisture/density for quality control in highway construction. 241Am neutron sources are also used in well logging applications, as well as in neutron radiography, tomography and other radiochemical investigations.
Yoshiwan Rakamu (ヨシワ星人ラカム, Yoshiwa Seijin Rakamu): Raenjo's daughter who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. She is held hostage by Rotmen until Hoji and Jasmine rescue her. Rakamu is portrayed by Mion Ono (小野 美音, Ono Mion). Chiman Tarewarane (チーマ星人タレワラーネ, Chīma Seijin Tarewarāne): A drug lord from Planet Chima who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster. Sometime prior to the special, he was deleted by Rui / Premiere Deka Red. Tarewarane is voiced by Kyōsuke Mano (真野 恭輔, Mano Kyōsuke). Ten Haretsuki (晴月 天, Haretsuki Ten): An S.P.D. officer and psychic with the ability to see precognitive dreams who works in S.P.D.'s Earth unit as Deka Pink Sono 2 (デカピンクその2, Deka Pinku Sono Ni) until she is transferred to another branch and appears exclusively in the web-exclusive crossover special Tokusou Sentai Dekaranger with Tombo Ohger. Ten Haretsuki is portrayed by Amisa Miyazaki (宮崎 あみさ, Miyazaki Amisa).
Because each chemical compound has a different chemical structure, each compound will have a unique (or almost unique) NMR spectrum. As a result, NMR is particularly useful for the characterization, identification and quantification of small molecules, such as metabolites. The widespread use of NMR for "classical" metabolic studies, along with its exceptional capacity to handle complex metabolite mixtures is likely the reason why NMR was one of the first technologies to be widely adopted for routine metabolome measurements. As an analytical technique, NMR is non-destructive, non-biased, easily quantifiable, requires little or no separation, permits the identification of novel compounds and it needs no chemical derivatization. NMR is particularly amenable to detecting compounds that are less tractable to LC-MS analysis, such as sugars, amines or volatile liquids or GC-MS analysis, such as large molecules (>500 Da) or relatively non-reactive compounds. NMR is not a very sensitive technique with a lower limit of detection of about 5 μM. Typically 50-150 compounds can be identified by NMR-based metabolomic studies. Mass spectrometry is an analytical technique that measures the mass-to-charge ratio of molecules. Molecules or molecular fragments are typically charged or ionized by spraying them through a charged field (electrospray ionization), bombarding them with electrons from a hot filament (electron ionization) or blasting them with a laser when they are placed on specially coated plates (matrix assisted laser desorption ionization).
Epulis fissuratum is a benign hyperplasia of fibrous connective tissue which develops as a reactive lesion to chronic mechanical irritation produced by the flange of a poorly fitting denture. More simply, epulis fissuratum is where excess folds of firm tissue form inside the mouth, as a result of rubbing on the edge of dentures that do not fit well. It is a harmless condition and does not represent oral cancer. Treatment is by simple surgical removal of the lesion, and also by adjustment of the denture or provision of a new denture. It is a closely related condition to inflammatory papillary hyperplasia, but the appearance and location differs.
Sources: en.wikipedia.org
=== Infantile-Onset (IOPD) === The infantile-onset (IOPD) form usually comes to medical attention within the first few months of life, either clinically or through newborn screening. The usual presenting features are cardiomyopathy, cardiomegaly, hypotonia, respiratory distress, muscle weakness, feeding difficulties, and failure to thrive. IOPD patients can be further classified by Cross-Reactive Immunological Material (CRIM) status which is an important predictor of clinical response. Patients that produce no GAA protein are referred to as CRIM negative. Therefore, they can develop highly sustained antibody titers for enzyme replacement therapy (ERT). Immunomodulation or immunotherapy is an effective treatment to prevent an immune response to ERT. The main clinical findings include floppy baby appearance, delayed motor milestones, and feeding difficulties. Moderate hepatomegaly may or may not be present. Facial features include macroglossia, hypernasal speech, hearing loss, and myopathic facies. Cardiopulmonary involvement is manifested by increased respiratory rate, use of accessory muscles for respiration, recurrent chest infections, decreased air entry in the left lower zone (due to cardiomegaly), arrhythmias, and evidence of heart failure. Before the development of a treatment, the median age at death in untreated cases was 8.7 months, usually due to cardiorespiratory failure. However, this outcome has drastically changed since enzyme replacement therapy became available, improving with early initiation of treatment.
April 9: Decree setting the structure, staffing, status, and pay for laboratory personnel (under the Ministry of Public Health): women may be assistants but may not hold leadership positions, nor the roles of head technician or "lab boy." October 30: Decree on child protection. October 30: Decree amending Articles 376 and following of the Civil Code; modifies the "right of parental discipline" — for both father and mother — and the terms and duration of placing a child under care. 1936
==== Oil window (temperature range) ==== Geologists often refer to the temperature range in which oil forms as an "oil window". Below the minimum temperature oil remains trapped in the form of kerogen. Above the maximum temperature the oil is converted to natural gas through the process of thermal cracking. Sometimes, oil formed at extreme depths may migrate and become trapped at a much shallower level. The Athabasca oil sands are one example of this.
The County of Schaumburg (not to be confused with the Principality of Schaumburg-Lippe) around the towns of Rinteln and Hessisch Oldendorf did indeed belong to the Prussian province of Hesse-Nassau until 1932, a province that also included large parts of the present state of Hesse, including the cities of Kassel, Wiesbaden and Frankfurt am Main; but in 1932 the County of Schaumburg became part of the Prussian Province of Hanover. When the Nazi Party seized power in 1933, they quickly transformed Germany into a highly centralised state and divided the entire Third Reich into Gaue which largely superseded (but did not outright replace) Germany's traditional federal system. Nevertheless, some changes to the old state and provincial borders were made in 1937, notably including the city of Cuxhaven being fully integrated into the Prussian Province of Hanover under the Greater Hamburg Act. The effect of this Nazi-era change was that in 1946, after the Third Reich had collapsed and when state of Lower Saxony was founded, only four states needed to be merged. With the exception of Bremen and the areas that were ceded to the Soviet Occupation Zone in 1945, all those areas allocated to the new state of Lower Saxony in 1946, had already been merged into the "Constituency Association of Lower Saxony" in 1920.
The Bailey peptide synthesis is a name reaction in organic chemistry developed 1949 by J. L. Bailey. It is a method for the synthesis of a peptide from α-amino acid-N-carboxylic acid anhydrides (NCAs) and amino acids or peptide esters. The reaction is characterized by short reaction times and a high yield of the target peptide. The reaction can be carried out at low temperatures in organic solvents. The residues R1 and R2 can be organic groups or hydrogen atoms, R3 is the used amino acid or peptide ester: The reaction mechanism is not known in detail. Supposedly, the reaction begins with a nucleophilic attack of the amino group on the carbonyl carbon of the anhydride group of the N-carboxylic acid anhydride (1). After an intramolecular proton migration, a 1,4-proton shift and the cleavage of carbon dioxide follows, resulting in the peptide bond in the final product (2):
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.